1	24	27	The	the	DT	_	_	B-cesDoc	B-text	B-body	B-div	B-head	_	_
2	28	35	problem	problem	NN	_	_	I-cesDoc	I-text	I-body	I-div	I-head	_	_
3	44	49	Three	three	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
4	50	59	published	publish	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
5	60	61	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
6	62	63	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
7	64	65	2	2	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
8	66	67	3	3	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
9	68	69	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
10	70	73	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
11	74	77	one	one	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
12	78	86	recently	recently	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
13	87	96	presented	present	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
14	97	98	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
15	99	100	4	4	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
16	109	110	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
17	111	121	randomized	randomize	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
18	122	140	placebo-controlled	placebo-controll	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
19	141	149	clinical	clinical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
20	150	155	trial	trial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
21	156	160	have	have	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
22	169	182	unequivocally	unequivocally	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
23	183	195	demonstrated	demonstrate	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
24	196	200	that	that	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
25	201	202	3	3	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
26	202	203	-	-	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
27	203	211	Hydroxy-	hydroxy-	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
28	211	212	3	3	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
29	212	213	-	-	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
30	213	227	methylgluatryl	methylgluatryl	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
31	236	244	coenzyme	coenzyme	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
32	245	246	A	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
33	247	248	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
34	248	251	HMG	hmg	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
35	252	255	CoA	coa	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
36	255	256	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
37	257	266	reductase	reductase	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
38	267	277	inhibitors	inhibitor	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
39	278	279	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
40	279	286	statins	statin	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
41	286	287	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
42	288	294	reduce	reduce	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
43	303	306	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
44	307	316	morbidity	morbidity	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
45	317	320	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
46	321	330	mortality	mortality	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
47	331	341	associated	associate	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
48	342	346	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
49	347	355	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
50	364	371	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
51	371	372	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
52	373	378	These	these	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
53	379	385	trials	trial	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
54	386	391	found	find	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
55	392	396	that	that	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
56	397	401	when	when	WRB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
57	402	410	compared	compare	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
58	411	415	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
59	424	431	placebo	placebo	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
60	431	432	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
61	433	440	statins	statin	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
62	441	454	significantly	significantly	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
63	455	462	reduced	reduce	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
64	463	466	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
65	467	476	incidence	incidence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
66	477	479	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
67	488	493	death	death	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
68	493	494	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
69	495	505	myocardial	myocardial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
70	506	516	infarction	infarction	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
71	516	517	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
72	518	526	unstable	unstable	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
73	527	533	angina	angina	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
74	533	534	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
75	535	547	percutaneous	percutaneous	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
76	556	559	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
77	560	568	surgical	surgical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
78	569	577	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
79	578	595	revascularization	revascularization	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
80	595	596	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
81	597	600	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
82	601	607	stroke	stroke	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
83	608	610	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
84	619	626	persons	person	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
85	627	631	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
86	641	647	stable	stable	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	B-hi
87	648	656	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
88	657	664	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
89	664	665	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
90	666	673	Because	because	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
91	682	690	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
92	691	694	who	who	WP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
93	695	698	had	have	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
94	699	710	experienced	experience	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
95	711	713	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
96	714	719	acute	acute	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
97	720	728	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
98	729	737	syndrome	syndrome	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
99	746	752	within	within	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
100	753	758	three	three	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
101	759	761	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
102	762	765	six	six	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
103	766	772	months	month	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
104	773	775	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
105	776	786	enrollment	enrollment	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
106	787	791	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
107	792	800	excluded	exclude	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
108	800	801	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
109	810	815	these	these	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
110	816	822	trials	trial	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
111	823	826	did	do	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
112	827	830	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
113	831	837	assess	assess	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
114	838	841	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
115	842	848	effect	effect	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
116	849	851	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
117	852	866	lipid-lowering	lipid-lower	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
118	875	882	therapy	therapy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
119	883	885	on	on	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
120	886	893	adverse	adverse	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
121	894	908	cardiovascular	cardiovascular	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
122	909	915	events	event	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
123	916	918	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
124	919	924	those	those	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
125	925	929	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
126	938	946	recently	recently	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
127	956	964	unstable	unstable	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	B-hi
128	965	973	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
129	974	981	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
130	981	982	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
131	983	990	Whether	whether	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
132	999	1013	lipid-lowering	lipid-lower	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
133	1014	1021	therapy	therapy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
134	1022	1027	would	would	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
135	1028	1035	provide	provide	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
136	1036	1047	incremental	incremental	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
137	1048	1055	benefit	benefit	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
138	1056	1058	if	if	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
139	1067	1076	initiated	initiate	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
140	1077	1088	immediately	immediately	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
141	1089	1098	following	follow	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
142	1099	1101	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
143	1102	1107	acute	acute	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
144	1108	1116	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
145	1117	1125	syndrome	syndrome	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
146	1134	1136	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
147	1137	1139	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
148	1140	1149	important	important	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
149	1150	1155	issue	issue	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
150	1156	1158	as	as	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
151	1159	1162	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
152	1163	1167	risk	risk	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
153	1168	1170	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
154	1171	1172	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
155	1173	1182	recurrent	recurrent	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
156	1183	1190	adverse	adverse	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
157	1199	1206	cardiac	cardiac	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
158	1207	1213	events	event	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
159	1214	1216	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
160	1217	1221	much	much	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
161	1222	1229	greater	greater	JJR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
162	1230	1232	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
163	1233	1241	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
164	1242	1246	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
165	1247	1255	unstable	unstable	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
166	1264	1272	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
167	1273	1280	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
168	1281	1285	than	than	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
169	1286	1288	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
170	1289	1292	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
171	1293	1299	stable	stable	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
172	1300	1307	setting	set	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
173	1307	1308	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
174	1309	1312	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
175	1313	1323	Myocardial	myocardial	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
176	1332	1340	Ischemia	ischemium	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
177	1341	1350	Reduction	reduction	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
178	1351	1355	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
179	1356	1366	Aggressive	aggressive	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
180	1367	1378	Cholesterol	cholesterol	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
181	1379	1387	Lowering	lower	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
182	1396	1397	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
183	1397	1403	MIRACL	miracl	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
184	1403	1404	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
185	1405	1410	trial	trial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
186	1411	1414	set	set	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
187	1415	1418	out	out	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
188	1419	1421	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
189	1422	1428	answer	answer	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
190	1429	1433	this	this	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
191	1434	1442	question	question	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
192	1442	1443	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
193	1466	1469	The	the	DT	_	_	I-cesDoc	I-text	I-body	B-div	B-head	_	_
194	1470	1476	answer	answer	NN	_	_	I-cesDoc	I-text	I-body	I-div	I-head	_	_
195	1476	1477	?	?	.	_	_	I-cesDoc	I-text	I-body	I-div	I-head	_	_
196	1486	1492	MIRACL	miracl	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
197	1493	1501	enrolled	enroll	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
198	1502	1507	3,086	3,086	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
199	1508	1516	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
200	1517	1523	within	within	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
201	1524	1526	24	24	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
202	1526	1527	-	-	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
203	1527	1529	96	96	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
204	1530	1535	hours	hour	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
205	1536	1537	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
206	1537	1541	mean	mean	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
207	1550	1552	63	63	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
208	1553	1558	hours	hour	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
209	1558	1559	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
210	1560	1562	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
211	1563	1572	admission	admission	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
212	1573	1576	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
213	1577	1585	unstable	unstable	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
214	1586	1592	angina	angina	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
215	1593	1595	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
216	1596	1597	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
217	1598	1602	non-	non-	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
218	1602	1604	Q-	q-	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
219	1604	1608	wave	wave	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
220	1617	1627	myocardial	myocardial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
221	1628	1638	infarction	infarction	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
222	1639	1642	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
223	1643	1653	randomized	randomize	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
224	1654	1658	them	them	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
225	1659	1661	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
226	1662	1664	16	16	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
227	1665	1670	weeks	week	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
228	1671	1673	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
229	1682	1694	atorvastatin	atorvastatin	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
230	1695	1697	80	80	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
231	1698	1700	mg	mg	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
232	1701	1703	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
233	1704	1711	placebo	placebo	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
234	1712	1716	once	once	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
235	1717	1722	daily	daily	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
236	1723	1724	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
237	1725	1726	5	5	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
238	1727	1728	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
239	1729	1730	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
240	1731	1734	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
241	1735	1740	major	major	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
242	1749	1758	exclusion	exclusion	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
243	1759	1767	criteria	criterion	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
244	1768	1772	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
245	1772	1773	:	:	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
246	1774	1779	total	total	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
247	1780	1791	cholesterol	cholesterol	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
248	1792	1797	level	level	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
249	1798	1805	greater	greater	JJR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
250	1814	1818	than	than	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
251	1819	1822	270	270	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
252	1823	1825	mg	mg	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
253	1825	1826	/	/	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
254	1826	1828	dL	dl	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
255	1828	1829	;	;	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
256	1830	1832	Q-	q-	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
257	1832	1836	wave	wave	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
258	1837	1847	myocardial	myocardial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
259	1848	1858	infarction	infarction	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
260	1859	1861	on	on	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
261	1862	1871	admission	admission	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
262	1880	1882	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
263	1883	1889	during	during	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
264	1890	1893	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
265	1894	1902	previous	previous	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
266	1903	1908	month	month	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
267	1908	1909	;	;	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
268	1910	1913	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
269	1913	1914	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
270	1915	1923	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
271	1932	1949	revascularization	revascularization	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
272	1950	1952	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
273	1953	1956	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
274	1957	1963	months	month	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
275	1964	1970	before	before	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
276	1971	1980	admission	admission	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
277	1980	1981	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
278	1982	1988	during	during	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
279	1997	2000	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
280	2001	2006	index	index	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
281	2007	2022	hospitalization	hospitalization	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
282	2023	2025	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
283	2026	2037	anticipated	anticipate	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
284	2038	2047	following	follow	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
285	2048	2056	hospital	hospital	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
286	2065	2074	discharge	discharge	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
287	2074	2075	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
288	2076	2079	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
289	2080	2087	primary	primary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
290	2088	2096	efficacy	efficacy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
291	2097	2105	endpoint	endpoint	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
292	2106	2109	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
293	2110	2111	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
294	2112	2121	composite	composite	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
295	2122	2124	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
296	2133	2138	death	death	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
297	2138	2139	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
298	2140	2149	non-fatal	non-fatal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
299	2150	2160	myocardial	myocardial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
300	2161	2171	infarction	infarction	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
301	2171	2172	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
302	2173	2185	resuscitated	resuscitate	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
303	2186	2192	sudden	sudden	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
304	2201	2208	cardiac	cardiac	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
305	2209	2214	death	death	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
306	2215	2217	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
307	2218	2226	emergent	emergent	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
308	2227	2244	rehospitalization	rehospitalization	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
309	2245	2248	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
310	2249	2258	worsening	worsen	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
311	2267	2278	symptomatic	symptomatic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
312	2279	2289	myocardial	myocardial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
313	2290	2298	ischemia	ischemium	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
314	2298	2299	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
315	2300	2309	Secondary	secondary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
316	2310	2319	endpoints	endpoint	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
317	2328	2336	included	include	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
318	2337	2343	stroke	stroke	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
319	2343	2344	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
320	2345	2354	worsening	worsen	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
321	2355	2360	heart	heart	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
322	2361	2368	failure	failure	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
323	2368	2369	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
324	2370	2374	need	need	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
325	2375	2378	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
326	2379	2387	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
327	2396	2413	revascularization	revascularization	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
328	2414	2417	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
329	2418	2424	change	change	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
330	2425	2427	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
331	2428	2433	lipid	lipid	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
332	2434	2440	levels	level	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
333	2441	2451	throughout	throughout	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
334	2452	2455	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
335	2464	2469	study	study	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
336	2469	2470	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
337	2471	2473	On	on	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
338	2474	2481	average	average	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
339	2481	2482	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
340	2483	2491	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
341	2492	2496	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
342	2497	2499	65	65	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
343	2500	2505	years	year	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
344	2506	2508	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
345	2509	2512	age	age	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
346	2512	2513	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
347	2522	2535	approximately	approximately	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
348	2536	2538	65	65	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
349	2538	2539	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
350	2540	2544	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
351	2545	2548	men	man	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
352	2548	2549	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
353	2550	2552	86	86	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
354	2552	2553	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
355	2554	2563	Caucasian	caucasian	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
356	2564	2567	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
357	2568	2571	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
358	2572	2576	mean	mean	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
359	2585	2593	baseline	baseline	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
360	2594	2597	low	low	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
361	2598	2605	density	density	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
362	2606	2617	lipoprotein	lipoprotein	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
363	2618	2619	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
364	2619	2622	LDL	ldl	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
365	2622	2623	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
366	2624	2635	cholesterol	cholesterol	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
367	2636	2641	level	level	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
368	2650	2653	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
369	2654	2657	124	124	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
370	2658	2660	mg	mg	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
371	2660	2661	/	/	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
372	2661	2663	dL	dl	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
373	2663	2664	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
374	2665	2677	Atorvastatin	atorvastatin	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
375	2678	2687	treatment	treatment	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
376	2688	2691	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
377	2692	2702	associated	associate	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
378	2703	2707	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
379	2708	2709	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
380	2718	2721	2.6	2.6	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
381	2721	2722	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
382	2723	2731	absolute	absolute	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
383	2732	2741	reduction	reduction	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
384	2742	2744	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
385	2745	2748	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
386	2749	2753	risk	risk	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
387	2754	2756	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
388	2757	2760	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
389	2761	2768	primary	primary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
390	2769	2777	endpoint	endpoint	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
391	2786	2787	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
392	2787	2791	14.8	14.8	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
393	2791	2792	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
394	2793	2796	vs.	vs.	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
395	2797	2801	17.4	17.4	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
396	2801	2802	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
397	2802	2803	;	;	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
398	2804	2806	RR	rr	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
399	2807	2815	relative	relative	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
400	2816	2820	risk	risk	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
401	2821	2822	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
402	2822	2824	RR	rr	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
403	2824	2825	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
404	2826	2830	0.84	0.84	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
405	2830	2831	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
406	2832	2834	95	95	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
407	2834	2835	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
408	2844	2854	confidence	confidence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
409	2855	2863	interval	interval	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
410	2864	2865	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
411	2865	2867	CI	cus	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
412	2867	2868	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
413	2869	2873	0.70	0.70	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
414	2873	2874	-	-	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
415	2874	2878	1.00	1.00	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
416	2878	2879	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
417	2880	2881	p	p	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
418	2882	2883	=	=	SYM	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
419	2884	2889	0.048	0.048	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
420	2889	2890	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
421	2890	2891	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
422	2892	2896	This	this	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
423	2905	2914	reduction	reduction	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
424	2915	2918	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
425	2919	2928	primarily	primarily	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
426	2929	2935	driven	drive	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
427	2936	2938	by	by	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
428	2939	2942	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
429	2943	2946	2.2	2.2	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
430	2946	2947	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
431	2948	2956	absolute	absolute	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
432	2965	2974	reduction	reduction	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
433	2975	2977	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
434	2978	2987	incidence	incidence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
435	2988	2990	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
436	2991	2999	emergent	emergent	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
437	3000	3017	rehospitalization	rehospitalization	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
438	3018	3021	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
439	3030	3041	symptomatic	symptomatic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
440	3042	3052	myocardial	myocardial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
441	3053	3061	ischemia	ischemium	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
442	3062	3063	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
443	3063	3066	6.2	6.2	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
444	3066	3067	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
445	3068	3071	vs.	vs.	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
446	3072	3075	8.4	8.4	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
447	3075	3076	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
448	3076	3077	;	;	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
449	3078	3080	RR	rr	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
450	3081	3085	0.74	0.74	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
451	3085	3086	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
452	3095	3097	95	95	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
453	3097	3098	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
454	3099	3101	CI	cus	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
455	3102	3106	0.57	0.57	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
456	3106	3107	-	-	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
457	3107	3111	0.95	0.95	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
458	3111	3112	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
459	3113	3114	p	p	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
460	3115	3116	=	=	SYM	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
461	3117	3121	0.02	0.02	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
462	3121	3122	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
463	3122	3123	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
464	3124	3127	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
465	3128	3132	risk	risk	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
466	3133	3135	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
467	3136	3141	death	death	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
468	3141	3142	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
469	3143	3151	nonfatal	nonfatal	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
470	3160	3170	myocardial	myocardial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
471	3171	3181	infarction	infarction	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
472	3182	3185	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
473	3186	3198	resuscitated	resuscitate	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
474	3199	3205	sudden	sudden	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
475	3206	3213	cardiac	cardiac	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
476	3214	3219	death	death	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
477	3228	3232	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
478	3233	3237	each	each	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
479	3238	3240	no	no	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
480	3241	3250	different	different	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
481	3251	3258	between	between	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
482	3259	3262	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
483	3263	3266	two	two	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
484	3267	3273	groups	group	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
485	3273	3274	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
486	3275	3280	While	while	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
487	3281	3286	there	there	EX	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
488	3295	3299	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
489	3300	3302	no	no	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
490	3303	3314	significant	significant	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
491	3315	3326	differences	difference	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
492	3327	3329	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
493	3330	3333	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
494	3334	3343	incidence	incidence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
495	3344	3346	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
496	3355	3364	worsening	worsen	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
497	3365	3370	heart	heart	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
498	3371	3378	failure	failure	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
499	3379	3381	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
500	3382	3386	need	need	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
501	3387	3390	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
502	3391	3399	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
503	3408	3425	revascularization	revascularization	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
504	3425	3426	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
505	3427	3439	atorvastatin	atorvastatin	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
506	3440	3443	did	do	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
507	3444	3450	reduce	reduce	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
508	3451	3454	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
509	3455	3464	incidence	incidence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
510	3465	3467	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
511	3476	3481	fatal	fatal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
512	3482	3484	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
513	3485	3494	non-fatal	non-fatal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
514	3495	3501	stroke	stroke	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
515	3502	3504	by	by	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
516	3505	3508	0.8	0.8	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
517	3508	3509	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
518	3510	3511	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
519	3511	3514	0.8	0.8	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
520	3514	3515	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
521	3516	3519	vs.	vs.	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
522	3520	3523	1.6	1.6	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
523	3523	3524	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
524	3524	3525	;	;	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
525	3526	3528	RR	rr	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
526	3529	3533	0.50	0.50	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
527	3533	3534	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
528	3543	3545	95	95	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
529	3545	3546	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
530	3547	3549	CI	cus	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
531	3550	3554	0.26	0.26	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
532	3554	3555	-	-	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
533	3555	3559	0.99	0.99	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
534	3559	3560	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
535	3561	3562	p	p	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
536	3563	3564	=	=	SYM	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
537	3565	3570	0.045	0.045	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
538	3570	3571	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
539	3571	3572	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
540	3573	3585	Atorvastatin	atorvastatin	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
541	3586	3590	also	also	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
542	3599	3612	significantly	significantly	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
543	3613	3620	reduced	reduce	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
544	3621	3626	total	total	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
545	3627	3630	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
546	3631	3634	LDL	ldl	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
547	3635	3646	cholesterol	cholesterol	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
548	3647	3650	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
549	3659	3671	triglyceride	triglyceride	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
550	3672	3678	levels	level	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
551	3679	3682	but	but	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
552	3683	3686	did	do	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
553	3687	3690	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
554	3691	3704	significantly	significantly	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
555	3705	3711	change	change	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
556	3712	3716	high	high	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
557	3725	3732	density	density	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
558	3733	3744	lipoprotein	lipoprotein	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
559	3745	3746	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
560	3746	3749	HDL	hdl	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
561	3749	3750	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
562	3751	3762	cholesterol	cholesterol	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
563	3763	3765	by	by	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
564	3766	3768	16	16	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
565	3769	3774	weeks	week	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
566	3774	3775	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
567	3776	3778	By	by	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
568	3779	3781	16	16	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
569	3790	3795	weeks	week	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
570	3795	3796	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
571	3797	3800	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
572	3801	3809	adjusted	adjusted	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
573	3810	3814	mean	mean	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
574	3815	3818	LDL	ldl	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
575	3819	3830	cholesterol	cholesterol	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
576	3831	3840	decreased	decrease	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
577	3841	3843	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
578	3844	3846	72	72	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
579	3855	3857	mg	mg	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
580	3857	3858	/	/	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
581	3858	3860	dL	dl	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
582	3861	3863	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
583	3864	3884	atorvastatin-treated	atorvastatin-treat	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
584	3885	3893	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
585	3894	3897	but	but	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
586	3898	3907	increased	increase	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
587	3908	3910	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
588	3911	3914	135	135	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
589	3923	3925	mg	mg	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
590	3925	3926	/	/	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
591	3926	3928	dL	dl	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
592	3929	3934	among	among	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
593	3935	3950	placebo-treated	placebo-treat	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
594	3951	3959	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
595	3959	3960	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
596	3961	3963	No	no	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
597	3964	3971	serious	serious	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
598	3972	3979	adverse	adverse	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
599	3988	3994	events	event	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
600	3995	4003	occurred	occur	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
601	4004	4006	as	as	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
602	4007	4010	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
603	4011	4017	result	result	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
604	4018	4020	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
605	4021	4030	treatment	treatment	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
606	4031	4035	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
607	4044	4056	atorvastatin	atorvastatin	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
608	4056	4057	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
609	4058	4066	although	although	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
610	4067	4077	reversible	reversible	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
611	4078	4083	liver	liver	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
612	4084	4096	transaminase	transaminase	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
613	4105	4114	elevation	elevation	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
614	4115	4119	more	more	JJR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
615	4120	4124	than	than	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
616	4125	4130	three	three	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
617	4131	4136	times	time	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
618	4137	4140	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
619	4141	4146	upper	upper	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
620	4147	4152	limit	limit	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
621	4153	4155	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
622	4156	4162	normal	normal	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
623	4171	4179	occurred	occur	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
624	4180	4182	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
625	4183	4186	2.5	2.5	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
626	4186	4187	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
627	4188	4190	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
628	4191	4211	atorvastatin-treated	atorvastatin-treat	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
629	4212	4218	versus	versus	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
630	4219	4222	0.6	0.6	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
631	4222	4223	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
632	4224	4226	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
633	4235	4250	placebo-treated	placebo-treat	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
634	4251	4259	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
635	4260	4261	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
636	4261	4262	p	p	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
637	4263	4264	<	<	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
638	4265	4270	0.001	0.001	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
639	4270	4271	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
640	4271	4272	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
641	4295	4298	The	the	DT	_	_	I-cesDoc	I-text	I-body	B-div	B-head	_	_
642	4299	4309	MIRACuLous	miraculous	NNP	_	_	I-cesDoc	I-text	I-body	I-div	I-head	_	_
643	4318	4321	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
644	4322	4330	efficacy	efficacy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
645	4331	4334	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
646	4335	4341	safety	safety	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
647	4342	4350	findings	finding	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
648	4351	4355	from	from	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
649	4356	4362	MIRACL	miracl	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
650	4363	4367	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
651	4368	4374	unique	unique	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
652	4383	4386	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
653	4387	4388	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
654	4389	4395	number	number	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
655	4396	4398	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
656	4399	4406	reasons	reason	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
657	4406	4407	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
658	4408	4416	Although	although	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
659	4417	4431	lipid-lowering	lipid-lower	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
660	4432	4439	therapy	therapy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
661	4448	4451	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
662	4452	4462	associated	associate	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
663	4463	4467	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
664	4468	4469	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
665	4470	4483	significantly	significantly	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
666	4484	4489	lower	lower	JJR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
667	4490	4499	mortality	mortality	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
668	4500	4504	when	when	WRB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
669	4513	4522	initiated	initiate	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
670	4523	4528	early	early	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
671	4529	4534	after	after	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
672	4535	4537	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
673	4538	4543	acute	acute	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
674	4544	4552	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
675	4553	4561	syndrome	syndrome	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
676	4562	4564	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
677	4565	4568	two	two	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
678	4577	4582	large	large	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
679	4583	4596	observational	observational	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
680	4597	4604	studies	study	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
681	4605	4606	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
682	4607	4608	6	6	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
683	4609	4610	7	7	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
684	4611	4612	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
685	4613	4614	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
686	4615	4621	MIRACL	miracl	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
687	4622	4625	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
688	4626	4629	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
689	4630	4635	first	first	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
690	4644	4654	randomized	randomize	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
691	4655	4660	trial	trial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
692	4661	4663	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
693	4664	4671	suggest	suggest	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
694	4672	4676	that	that	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
695	4677	4684	statins	statin	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
696	4685	4691	confer	confer	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
697	4692	4700	clinical	clinical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
698	4709	4717	benefits	benefit	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
699	4718	4720	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
700	4721	4725	this	this	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
701	4726	4733	setting	set	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
702	4733	4734	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
703	4735	4737	It	it	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
704	4738	4741	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
705	4742	4746	also	also	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
706	4747	4750	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
707	4751	4756	first	first	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
708	4757	4762	trial	trial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
709	4763	4765	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
710	4774	4782	identify	identify	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
711	4783	4784	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
712	4785	4795	short-term	short-term	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
713	4796	4797	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
714	4797	4799	ie	ie	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
715	4799	4800	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
716	4801	4807	within	within	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
717	4808	4810	16	16	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
718	4811	4816	weeks	week	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
719	4816	4817	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
720	4818	4826	clinical	clinical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
721	4835	4842	benefit	benefit	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
722	4843	4847	from	from	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
723	4848	4854	statin	statin	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
724	4855	4862	therapy	therapy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
725	4862	4863	;	;	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
726	4864	4866	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
727	4867	4875	previous	previous	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
728	4876	4885	secondary	secondary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
729	4894	4904	prevention	prevention	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
730	4905	4911	trials	trial	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
731	4911	4912	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
732	4913	4916	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
733	4917	4924	benefit	benefit	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
734	4925	4927	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
735	4928	4934	statin	statin	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
736	4935	4942	therapy	therapy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
737	4943	4946	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
738	4947	4950	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
739	4959	4966	evident	evident	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
740	4967	4970	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
741	4971	4974	one	one	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
742	4975	4977	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
743	4978	4981	two	two	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
744	4982	4987	years	year	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
745	4987	4988	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
746	4989	4992	And	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
747	4992	4993	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
748	4994	4999	while	while	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
749	5000	5008	clinical	clinical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
750	5009	5014	trial	trial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
751	5023	5029	safety	safety	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
752	5030	5039	endpoints	endpoint	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
753	5040	5043	may	may	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
754	5044	5046	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
755	5047	5057	considered	consider	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
756	5058	5062	less	less	RBR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
757	5063	5072	glamorous	glamorous	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
758	5072	5073	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
759	5074	5080	MIRACL	miracl	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
760	5080	5082	's	be	POS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
761	5091	5095	most	most	RBS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
762	5096	5105	important	important	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
763	5106	5118	contribution	contribution	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
764	5119	5122	may	may	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
765	5123	5127	have	have	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
766	5128	5132	been	be	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
767	5133	5137	that	that	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
768	5138	5147	high-dose	high-dose	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
769	5156	5162	statin	statin	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
770	5163	5170	therapy	therapy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
771	5171	5174	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
772	5175	5178	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
773	5179	5189	associated	associate	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
774	5190	5194	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
775	5195	5202	serious	serious	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
776	5203	5207	harm	harm	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
777	5207	5208	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
778	5217	5224	despite	despite	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
779	5225	5228	its	its	PRP$	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
780	5229	5232	use	use	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
781	5233	5235	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
782	5236	5239	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
783	5240	5248	unstable	unstable	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
784	5249	5256	setting	set	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
785	5256	5257	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
786	5258	5265	Earlier	earlier	RBR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
787	5266	5275	secondary	secondary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
788	5284	5294	prevention	prevention	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
789	5295	5301	statin	statin	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
790	5302	5308	trials	trial	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
791	5309	5312	had	have	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
792	5313	5321	excluded	exclude	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
793	5322	5330	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
794	5331	5335	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
795	5344	5352	unstable	unstable	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
796	5353	5361	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
797	5362	5371	syndromes	syndrome	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
798	5372	5379	largely	largely	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
799	5380	5383	out	out	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
800	5384	5386	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
801	5387	5398	theoretical	theoretical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
802	5407	5414	concern	concern	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
803	5415	5419	that	that	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
804	5420	5435	statin-mediated	statin-mediate	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
805	5436	5446	reductions	reduction	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
806	5447	5449	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
807	5450	5458	vascular	vascular	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
808	5459	5465	smooth	smooth	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
809	5474	5480	muscle	muscle	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
810	5481	5485	cell	cell	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
811	5486	5499	proliferation	proliferation	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
812	5500	5505	might	may	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
813	5506	5517	destabilize	destabilize	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
814	5518	5525	healing	heal	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
815	5526	5532	plaque	plaque	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
816	5532	5533	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
817	5542	5546	That	that	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
818	5547	5549	no	no	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
819	5550	5554	harm	harm	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
820	5555	5563	resulted	result	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
821	5564	5568	from	from	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
822	5569	5573	this	this	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
823	5574	5584	aggressive	aggressive	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
824	5585	5594	treatment	treatment	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
825	5603	5611	strategy	strategy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
826	5612	5618	should	should	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
827	5619	5624	allay	allay	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
828	5625	5636	theoretical	theoretical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
829	5637	5642	fears	fear	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
830	5643	5646	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
831	5647	5649	by	by	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
832	5650	5655	doing	do	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
833	5656	5658	so	so	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
834	5667	5673	remove	remove	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
835	5674	5675	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
836	5676	5681	major	major	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
837	5682	5690	obstacle	obstacle	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
838	5691	5693	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
839	5694	5697	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
840	5698	5707	inpatient	inpatient	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
841	5708	5718	initiation	initiation	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
842	5719	5721	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
843	5730	5742	lipid-lowing	lipid-low	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
844	5743	5750	therapy	therapy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
845	5751	5756	after	after	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
846	5757	5765	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
847	5766	5772	events	event	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
848	5772	5773	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
849	5796	5799	The	the	DT	_	_	I-cesDoc	I-text	I-body	B-div	B-head	_	_
850	5800	5803	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	I-head	_	_
851	5804	5806	so	so	RB	_	_	I-cesDoc	I-text	I-body	I-div	I-head	_	_
852	5807	5817	MIRACuLous	miraculous	NNP	_	_	I-cesDoc	I-text	I-body	I-div	I-head	_	_
853	5826	5833	Despite	despite	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
854	5834	5839	these	these	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
855	5840	5846	unique	unique	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
856	5847	5850	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
857	5851	5860	important	important	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
858	5861	5869	findings	finding	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
859	5869	5870	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
860	5871	5876	there	there	EX	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
861	5877	5881	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
862	5890	5891	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
863	5892	5898	number	number	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
864	5899	5901	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
865	5902	5910	inherent	inherent	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
866	5911	5916	study	study	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
867	5917	5928	limitations	limitation	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
868	5929	5934	worth	worth	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
869	5935	5941	noting	note	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
870	5941	5942	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
871	5943	5948	First	first	LS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
872	5957	5960	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
873	5961	5969	foremost	foremost	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
874	5969	5970	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
875	5971	5974	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
876	5975	5986	possibility	possibility	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
877	5987	5989	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
878	5990	5991	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
879	5992	5996	null	null	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
880	5997	6006	treatment	treatment	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
881	6007	6013	effect	effect	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
882	6022	6025	can	can	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
883	6025	6028	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
884	6029	6031	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
885	6032	6039	ignored	ignore	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
886	6040	6045	given	give	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
887	6046	6049	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
888	6050	6054	wide	wide	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
889	6055	6065	confidence	confidence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
890	6066	6075	intervals	interval	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
891	6076	6077	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
892	6077	6080	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
893	6089	6094	hence	hence	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
894	6095	6105	marginally	marginally	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
895	6106	6117	significant	significant	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
896	6118	6119	p	p	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
897	6120	6125	value	value	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
898	6126	6128	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
899	6129	6134	0.048	0.048	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
900	6134	6135	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
901	6136	6139	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
902	6140	6143	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
903	6152	6158	effect	effect	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
904	6159	6161	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
905	6162	6174	atorvastatin	atorvastatin	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
906	6175	6177	on	on	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
907	6178	6181	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
908	6182	6189	primary	primary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
909	6190	6198	efficacy	efficacy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
910	6199	6207	endpoint	endpoint	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
911	6207	6208	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
912	6217	6228	Furthermore	furthermore	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
913	6228	6229	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
914	6230	6235	while	while	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
915	6236	6239	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
916	6240	6246	number	number	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
917	6247	6249	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
918	6250	6258	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
919	6259	6263	lost	lose	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
920	6264	6266	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
921	6267	6273	follow	follow	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
922	6274	6276	up	up	RP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
923	6285	6288	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
924	6289	6294	small	small	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
925	6294	6295	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
926	6296	6298	if	if	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
927	6299	6306	adverse	adverse	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
928	6307	6313	events	event	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
929	6314	6317	had	have	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
930	6318	6326	occurred	occur	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
931	6327	6329	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
932	6330	6335	those	those	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
933	6336	6343	treated	treat	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
934	6352	6356	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
935	6357	6369	atorvastatin	atorvastatin	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
936	6370	6371	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
937	6371	6372	n	n	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
938	6373	6374	=	=	SYM	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
939	6375	6376	3	3	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
940	6376	6377	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
941	6378	6381	but	but	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
942	6382	6385	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
943	6386	6393	placebo	placebo	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
944	6394	6395	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
945	6395	6396	n	n	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
946	6397	6398	=	=	SYM	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
947	6399	6400	8	8	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
948	6400	6401	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
949	6401	6402	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
950	6403	6406	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
951	6415	6422	overall	overall	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
952	6423	6428	trial	trial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
953	6429	6436	results	result	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
954	6437	6440	may	may	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
955	6441	6445	have	have	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
956	6446	6450	been	be	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
957	6451	6458	neutral	neutral	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
958	6459	6465	rather	rather	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
959	6466	6470	than	than	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
960	6479	6487	positive	positive	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
961	6487	6488	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
962	6497	6500	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
963	6501	6506	types	type	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
964	6507	6509	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
965	6510	6516	events	event	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
966	6517	6526	prevented	prevent	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
967	6527	6529	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
968	6530	6536	MIRACL	miracl	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
969	6537	6540	are	be	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
970	6541	6545	also	also	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
971	6546	6551	worth	worth	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
972	6560	6566	noting	note	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
973	6566	6567	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
974	6568	6573	While	while	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
975	6574	6591	rehospitalization	rehospitalization	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
976	6592	6595	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
977	6596	6605	recurrent	recurrent	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
978	6606	6616	myocardial	myocardial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
979	6625	6633	ischemia	ischemium	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
980	6634	6636	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
981	6637	6639	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
982	6640	6649	important	important	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
983	6650	6661	determinant	determinant	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
984	6662	6664	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
985	6665	6672	quality	quality	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
986	6673	6675	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
987	6676	6680	life	life	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
988	6681	6684	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
989	6693	6699	health	health	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
990	6700	6704	care	care	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
991	6705	6710	costs	cost	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
992	6710	6711	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
993	6712	6717	other	other	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
994	6718	6727	important	important	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
995	6728	6737	endpoints	endpoint	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
996	6738	6742	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
997	6743	6746	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
998	6755	6768	significantly	significantly	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
999	6769	6777	affected	affect	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1000	6778	6779	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1001	6779	6781	eg	eg	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1002	6781	6782	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1003	6783	6788	death	death	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1004	6788	6789	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1005	6790	6800	myocardial	myocardial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1006	6801	6811	infarction	infarction	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1007	6811	6812	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1008	6821	6833	resuscitated	resuscitate	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1009	6834	6840	sudden	sudden	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1010	6841	6848	cardiac	cardiac	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1011	6849	6854	death	death	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1012	6854	6855	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1013	6856	6865	worsening	worsen	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1014	6866	6871	heart	heart	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1015	6872	6879	failure	failure	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1016	6879	6880	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1017	6889	6893	need	need	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1018	6894	6897	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1019	6898	6906	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1020	6907	6924	revascularization	revascularization	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1021	6924	6925	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1022	6926	6929	etc	etc	FW	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1023	6929	6930	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1024	6930	6931	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1025	6932	6935	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1026	6936	6944	question	question	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1027	6945	6947	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1028	6956	6963	whether	whether	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1029	6964	6971	statins	statin	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1030	6972	6975	can	can	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1031	6976	6983	prevent	prevent	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1032	6984	6989	these	these	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1033	6990	6993	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1034	6994	6999	other	other	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1035	7000	7007	adverse	adverse	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1036	7008	7014	events	event	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1037	7023	7027	when	when	WRB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1038	7028	7037	initiated	initiate	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1039	7038	7042	soon	soon	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1040	7043	7048	after	after	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1041	7049	7051	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1042	7052	7057	acute	acute	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1043	7058	7066	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1044	7067	7075	syndrome	syndrome	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1045	7076	7080	will	will	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1046	7089	7096	require	require	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1047	7097	7104	further	further	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1048	7105	7110	study	study	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1049	7110	7111	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1050	7120	7123	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
1051	7124	7129	short	short	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1052	7130	7138	duration	duration	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1053	7139	7141	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1054	7142	7151	follow-up	follow-up	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1055	7152	7154	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1056	7155	7159	also	also	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1057	7160	7172	particularly	particularly	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1058	7181	7190	troubling	trouble	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1059	7190	7191	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1060	7192	7197	While	while	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1061	7198	7200	it	it	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1062	7201	7203	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1063	7204	7214	impressive	impressive	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1064	7215	7219	that	that	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1065	7220	7221	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1066	7222	7230	clinical	clinical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1067	7231	7238	benefit	benefit	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1068	7247	7250	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1069	7251	7259	realized	realize	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1070	7260	7265	after	after	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1071	7266	7270	only	only	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1072	7271	7273	16	16	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1073	7274	7279	weeks	week	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1074	7280	7282	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1075	7283	7289	statin	statin	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1076	7290	7297	therapy	therapy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1077	7297	7298	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1078	7299	7302	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1079	7311	7320	increased	increased	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1080	7321	7325	risk	risk	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1081	7326	7328	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1082	7329	7336	adverse	adverse	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1083	7337	7345	clinical	clinical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1084	7346	7352	events	event	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1085	7353	7361	persists	persist	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1086	7370	7380	throughout	throughout	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1087	7381	7384	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1088	7385	7389	year	year	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1089	7390	7399	following	follow	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1090	7400	7402	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1091	7403	7408	acute	acute	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1092	7409	7417	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1093	7418	7426	syndrome	syndrome	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1094	7426	7427	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1095	7436	7443	Without	without	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1096	7444	7450	longer	longer	RBR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1097	7451	7459	clinical	clinical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1098	7460	7466	follow	follow	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1099	7467	7469	up	up	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1100	7469	7470	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1101	7471	7473	it	it	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1102	7474	7476	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1103	7477	7480	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1104	7481	7489	possible	possible	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1105	7490	7492	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1106	7501	7507	assess	assess	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1107	7508	7511	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1108	7512	7529	intermediate-term	intermediate-term	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1109	7530	7536	effect	effect	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1110	7537	7538	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1111	7538	7540	if	if	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1112	7541	7544	any	any	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1113	7544	7545	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1114	7546	7548	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1115	7557	7569	atorvastatin	atorvastatin	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1116	7570	7572	on	on	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1117	7573	7577	hard	hard	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1118	7578	7587	endpoints	endpoint	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1119	7588	7592	such	such	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1120	7593	7595	as	as	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1121	7596	7601	death	death	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1122	7602	7604	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1123	7605	7615	myocardial	myocardial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1124	7624	7634	infarction	infarction	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1125	7634	7635	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1126	7636	7638	To	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1127	7639	7641	do	do	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1128	7642	7644	so	so	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1129	7645	7650	would	would	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1130	7651	7653	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1131	7654	7662	critical	critical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1132	7663	7665	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1133	7666	7671	light	light	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1134	7672	7674	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1135	7675	7678	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1136	7679	7683	lack	lack	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1137	7692	7694	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1138	7695	7701	effect	effect	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1139	7702	7704	on	on	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1140	7705	7710	these	these	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1141	7711	7720	important	important	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1142	7721	7730	endpoints	endpoint	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1143	7731	7733	at	at	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1144	7734	7736	16	16	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1145	7737	7742	weeks	week	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1146	7742	7743	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1147	7752	7765	Unfortunately	unfortunately	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1148	7765	7766	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1149	7767	7769	no	no	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1150	7770	7774	late	late	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1151	7775	7783	clinical	clinical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1152	7784	7790	follow	follow	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1153	7791	7793	up	up	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1154	7794	7796	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1155	7797	7804	planned	plan	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1156	7804	7805	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1157	7814	7819	There	there	EX	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
1158	7820	7824	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1159	7825	7829	also	also	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1160	7830	7831	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1161	7832	7838	number	number	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1162	7839	7841	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1163	7842	7853	limitations	limitation	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1164	7854	7858	that	that	WDT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1165	7859	7862	may	may	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1166	7863	7867	have	have	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1167	7876	7884	hampered	hamper	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1168	7885	7888	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1169	7889	7894	study	study	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1170	7894	7896	's	be	POS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1171	7897	7913	generalizability	generalizability	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1172	7913	7914	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1173	7915	7920	First	first	LS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1174	7920	7921	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1175	7922	7930	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1176	7931	7934	who	who	WP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1177	7943	7952	underwent	undergo	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1178	7953	7959	recent	recent	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1179	7960	7977	revascularization	revascularization	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1180	7978	7980	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1181	7981	7983	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1182	7984	7988	whom	whom	WP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1183	7989	7991	it	it	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1184	7992	7995	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1185	8004	8011	planned	plan	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1186	8012	8016	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1187	8017	8025	excluded	exclude	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1188	8025	8026	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1189	8027	8039	Specifically	specifically	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1190	8039	8040	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1191	8041	8049	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1192	8050	8053	who	who	WP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1193	8054	8063	underwent	undergo	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1194	8072	8084	percutaneous	percutaneous	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1195	8085	8097	transluminal	transluminal	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1196	8098	8106	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1197	8107	8118	angioplasty	angioplasty	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1198	8119	8120	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1199	8120	8124	PTCA	ptca	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1200	8124	8125	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1201	8126	8128	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1202	8137	8145	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1203	8146	8152	artery	artery	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1204	8153	8159	bypass	bypass	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1205	8160	8165	graft	graft	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1206	8166	8167	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1207	8167	8171	CABG	cabg	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1208	8171	8172	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1209	8173	8180	surgery	surgery	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1210	8181	8187	within	within	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1211	8188	8191	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1212	8200	8208	previous	previous	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1213	8209	8214	three	three	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1214	8215	8217	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1215	8218	8221	six	six	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1216	8222	8228	months	month	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1217	8229	8241	respectively	respectively	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1218	8242	8246	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1219	8247	8250	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1220	8251	8259	eligible	eligible	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1221	8268	8271	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1222	8272	8281	inclusion	inclusion	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1223	8281	8282	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1224	8283	8286	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1225	8287	8300	investigators	investigator	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1226	8301	8309	reasoned	reason	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1227	8310	8314	that	that	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1228	8315	8324	recurrent	recurrent	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1229	8333	8341	ischemic	ischemic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1230	8342	8348	events	event	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1231	8349	8351	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1232	8352	8356	this	this	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1233	8357	8367	population	population	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1234	8368	8372	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1235	8373	8379	likely	likely	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1236	8380	8382	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1237	8383	8389	result	result	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1238	8398	8402	from	from	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1239	8403	8413	restenosis	restenosis	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1240	8414	8416	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1241	8417	8423	bypass	bypass	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1242	8424	8429	graft	graft	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1243	8430	8437	closure	closure	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1244	8438	8441	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1245	8442	8446	that	that	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1246	8447	8454	statins	statin	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1247	8463	8468	would	would	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1248	8469	8471	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1249	8472	8476	less	less	RBR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1250	8477	8483	likely	likely	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1251	8484	8486	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1252	8487	8493	affect	affect	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1253	8494	8499	these	these	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1254	8500	8509	processes	process	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1255	8510	8511	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1256	8512	8513	8	8	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1257	8514	8515	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1258	8516	8517	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1259	8526	8538	Nevertheless	nevertheless	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1260	8538	8539	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1261	8540	8541	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1262	8542	8548	number	number	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1263	8549	8551	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1264	8552	8558	trials	trial	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1265	8559	8563	have	have	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1266	8564	8575	established	establish	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1267	8576	8579	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1268	8588	8596	benefits	benefit	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1269	8597	8599	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1270	8600	8606	statin	statin	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1271	8607	8614	therapy	therapy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1272	8624	8629	early	early	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	B-hi
1273	8630	8635	after	after	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1274	8636	8644	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1275	8653	8670	revascularization	revascularization	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1276	8671	8672	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1277	8673	8674	9	9	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1278	8675	8677	10	10	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1279	8678	8680	11	11	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1280	8681	8682	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1281	8683	8684	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1282	8685	8696	Furthermore	furthermore	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1283	8696	8697	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1284	8698	8699	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1285	8700	8706	number	number	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1286	8707	8709	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1287	8718	8724	recent	recent	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1288	8725	8731	trials	trial	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1289	8732	8736	have	have	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1290	8737	8746	suggested	suggest	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1291	8747	8751	that	that	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1292	8752	8758	higher	higher	JJR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1293	8759	8763	risk	risk	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1294	8764	8772	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1295	8773	8777	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1296	8786	8790	non-	non-	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1297	8790	8792	ST	st	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1298	8793	8802	elevation	elevation	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1299	8803	8808	acute	acute	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1300	8809	8817	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1301	8818	8827	syndromes	syndrome	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1302	8828	8832	fair	fair	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1303	8833	8839	better	better	JJR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1304	8840	8844	when	when	WRB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1305	8853	8855	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1306	8856	8861	early	early	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1307	8862	8870	invasive	invasive	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1308	8871	8879	strategy	strategy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1309	8880	8882	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1310	8883	8890	applied	apply	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1311	8891	8892	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1312	8893	8895	12	12	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1313	8896	8898	13	13	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1314	8899	8901	14	14	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1315	8902	8903	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1316	8904	8907	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1317	8908	8910	it	it	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1318	8919	8921	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1319	8922	8925	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1320	8926	8934	uncommon	uncommon	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1321	8935	8938	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1322	8939	8947	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1323	8948	8950	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1324	8951	8953	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1325	8954	8961	treated	treat	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1326	8962	8964	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1327	8965	8969	this	this	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1328	8970	8977	fashion	fashion	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1329	8977	8978	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1330	8987	8993	Second	second	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1331	8993	8994	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1332	8995	9003	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1333	9004	9008	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1334	9009	9011	Q-	q-	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1335	9011	9015	wave	wave	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1336	9016	9026	myocardial	myocardial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1337	9027	9037	infarction	infarction	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1338	9038	9042	were	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1339	9043	9046	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1340	9055	9063	eligible	eligible	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1341	9064	9067	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1342	9068	9078	enrollment	enrollment	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1343	9079	9086	because	because	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1344	9087	9089	it	it	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1345	9090	9093	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1346	9094	9098	felt	feel	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1347	9099	9103	that	that	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1348	9104	9111	statins	statin	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1349	9120	9125	would	would	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1350	9126	9129	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1351	9130	9139	influence	influence	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1352	9140	9143	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1353	9144	9155	development	development	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1354	9156	9158	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1355	9159	9168	important	important	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1356	9169	9179	prognostic	prognostic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1357	9188	9200	determinants	determinant	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1358	9201	9205	such	such	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1359	9206	9208	as	as	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1360	9209	9213	left	leave	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1361	9214	9225	ventricular	ventricular	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1362	9226	9234	systolic	systolic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1363	9235	9246	dysfunction	dysfunction	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1364	9246	9247	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1365	9256	9267	ventricular	ventricular	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1366	9268	9279	arrhythmias	arrhythmia	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1367	9280	9282	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1368	9283	9293	mechanical	mechanical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1369	9294	9307	complications	complication	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1370	9308	9309	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1371	9310	9311	5	5	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1372	9312	9313	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1373	9314	9315	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1374	9324	9336	Nevertheless	nevertheless	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1375	9336	9337	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1376	9338	9346	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1377	9347	9350	who	who	WP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1378	9351	9358	develop	develop	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1379	9359	9379	electrocardiographic	electrocardiographic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1380	9388	9390	Q-	q-	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1381	9390	9395	waves	wave	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1382	9396	9405	represent	represent	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1383	9406	9407	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1384	9408	9419	substantial	substantial	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1385	9420	9430	proportion	proportion	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1386	9431	9433	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1387	9434	9437	all	all	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1388	9438	9446	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1389	9455	9459	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1390	9460	9470	myocardial	myocardial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1391	9471	9481	infarction	infarction	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1392	9481	9482	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1393	9483	9488	While	while	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1394	9489	9494	their	their	PRP$	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1395	9495	9505	short-term	short-term	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1396	9506	9510	risk	risk	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1397	9519	9528	following	follow	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1398	9529	9537	hospital	hospital	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1399	9538	9547	discharge	discharge	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1400	9548	9550	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1401	9551	9556	lower	lower	JJR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1402	9557	9565	relative	relative	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1403	9566	9568	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1404	9569	9574	those	those	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1405	9583	9587	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1406	9588	9589	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1407	9590	9594	non-	non-	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1408	9594	9596	Q-	q-	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1409	9596	9600	wave	wave	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1410	9601	9611	myocardial	myocardial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1411	9612	9622	infarction	infarction	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1412	9622	9623	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1413	9624	9626	it	it	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1414	9627	9629	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1415	9630	9635	still	still	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1416	9636	9640	much	much	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1417	9649	9656	greater	greater	JJR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1418	9657	9661	than	than	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1419	9662	9664	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1420	9665	9673	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1421	9674	9678	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1422	9679	9685	stable	stable	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1423	9686	9694	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1424	9695	9702	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1425	9702	9703	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1426	9704	9707	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1427	9716	9719	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1428	9720	9724	need	need	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1429	9725	9728	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1430	9729	9738	secondary	secondary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1431	9739	9749	prevention	prevention	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1432	9750	9752	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1433	9753	9757	this	this	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1434	9758	9768	population	population	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1435	9769	9771	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1436	9780	9787	equally	equally	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1437	9788	9797	important	important	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1438	9797	9798	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1439	9799	9804	Third	third	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1440	9804	9805	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1441	9806	9813	despite	despite	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1442	9814	9817	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1443	9818	9822	high	high	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1444	9823	9827	risk	risk	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1445	9828	9834	nature	nature	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1446	9835	9837	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1447	9846	9854	enrolled	enroll	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1448	9855	9863	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1449	9864	9865	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1450	9865	9867	ie	ie	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1451	9867	9868	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1452	9869	9886	electrocardiogram	electrocardiogram	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1453	9887	9888	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1454	9888	9891	ECG	ecg	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1455	9891	9892	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1456	9893	9900	changes	change	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1457	9909	9912	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1458	9912	9913	/	/	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1459	9913	9915	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1460	9916	9921	other	other	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1461	9922	9931	objective	objective	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1462	9932	9940	evidence	evidence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1463	9941	9943	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1464	9944	9952	ischemia	ischemium	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1465	9952	9953	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1466	9953	9954	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1467	9955	9958	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1468	9959	9963	rate	rate	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1469	9964	9966	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1470	9975	9983	platelet	platelet	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1471	9984	9996	glycoprotein	glycoprotein	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1472	9997	10000	IIb	iib	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1473	10000	10001	/	/	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1474	10001	10005	IIIa	iium	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1475	10006	10015	inhibitor	inhibitor	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1476	10016	10027	utilization	utilization	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1477	10028	10031	was	be	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1478	10040	10045	quite	quite	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1479	10046	10049	low	low	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1480	10050	10051	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1481	10051	10054	1.1	1.1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1482	10054	10055	%	%	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1483	10055	10056	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1484	10056	10057	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1485	10058	10062	Such	such	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1486	10063	10070	therapy	therapy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1487	10071	10078	appears	appear	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1488	10079	10081	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1489	10082	10084	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1490	10085	10089	cost	cost	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1491	10090	10099	effective	effective	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1492	10108	10109	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1493	10110	10112	15	15	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1494	10113	10115	16	16	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1495	10116	10117	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1496	10118	10119	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1497	10120	10130	especially	especially	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1498	10131	10136	among	among	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1499	10137	10141	high	high	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1500	10142	10146	risk	risk	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1501	10147	10155	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1502	10156	10159	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1503	10160	10162	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1504	10171	10182	recommended	recommend	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1505	10183	10188	under	under	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1506	10189	10196	current	current	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1507	10197	10205	American	american	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1508	10206	10213	College	college	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1509	10214	10216	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1510	10225	10235	Cardiology	cardiology	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1511	10235	10236	/	/	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1512	10236	10244	American	american	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1513	10245	10250	Heart	heart	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1514	10251	10262	Association	association	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1515	10263	10273	guidelines	guideline	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1516	10274	10275	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1517	10276	10278	17	17	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1518	10279	10280	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1519	10281	10282	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1520	10291	10297	Fourth	fourth	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1521	10297	10298	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1522	10299	10301	it	it	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1523	10302	10305	may	may	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1524	10306	10309	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1525	10310	10312	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1526	10313	10321	possible	possible	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1527	10322	10324	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1528	10325	10334	ascertain	ascertain	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1529	10335	10342	whether	whether	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1530	10343	10348	these	these	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1531	10357	10365	findings	finding	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1532	10366	10371	apply	apply	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1533	10372	10374	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1534	10375	10378	all	all	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1535	10379	10387	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1536	10388	10392	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1537	10393	10399	recent	recent	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1538	10400	10405	acute	acute	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1539	10406	10414	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1540	10423	10432	syndromes	syndrome	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1541	10433	10443	regardless	regardless	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1542	10444	10446	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1543	10447	10455	baseline	baseline	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1544	10456	10461	lipid	lipid	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1545	10462	10468	levels	level	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1546	10468	10469	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1547	10470	10473	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1548	10474	10479	small	small	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1549	10488	10498	difference	difference	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1550	10499	10501	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1551	10502	10508	number	number	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1552	10509	10511	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1553	10512	10519	primary	primary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1554	10520	10528	endpoint	endpoint	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1555	10529	10535	events	event	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1556	10536	10543	between	between	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1557	10552	10564	atorvastatin	atorvastatin	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1558	10565	10568	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1559	10569	10576	placebo	placebo	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1560	10577	10583	groups	group	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1561	10584	10588	make	make	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1562	10589	10591	it	it	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1563	10592	10601	difficult	difficult	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1564	10602	10604	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1565	10613	10620	dissect	dissect	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1566	10621	10624	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1567	10625	10637	relationship	relationship	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1568	10638	10645	between	between	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1569	10646	10654	baseline	baseline	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1570	10655	10660	lipid	lipid	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1571	10661	10667	levels	level	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1572	10668	10671	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1573	10680	10689	treatment	treatment	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1574	10690	10696	effect	effect	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1575	10697	10704	further	further	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1576	10704	10705	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1577	10706	10718	Consequently	consequently	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1578	10718	10719	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1579	10720	10722	it	it	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1580	10723	10730	remains	remains	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1581	10739	10748	uncertain	uncertain	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1582	10749	10756	whether	whether	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1583	10757	10760	one	one	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1584	10761	10764	can	can	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1585	10765	10776	extrapolate	extrapolate	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1586	10777	10780	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1587	10781	10787	MIRACL	miracl	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1588	10788	10793	trial	trial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1589	10802	10809	results	result	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1590	10810	10812	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1591	10813	10818	those	those	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1592	10819	10822	who	who	WP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1593	10823	10830	undergo	undergo	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1594	10831	10839	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1595	10840	10857	revascularization	revascularization	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1596	10866	10873	shortly	shortly	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1597	10874	10880	before	before	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1598	10881	10883	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1599	10884	10889	after	after	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1600	10890	10891	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1601	10892	10900	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1602	10901	10906	event	event	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1603	10906	10907	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1604	10908	10911	who	who	WP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1605	10912	10919	present	present	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1606	10920	10924	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1607	10933	10934	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1608	10935	10937	Q-	q-	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1609	10937	10941	wave	wave	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1610	10942	10952	myocardial	myocardial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1611	10953	10963	infarction	infarction	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1612	10963	10964	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1613	10965	10968	who	who	WP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1614	10969	10972	are	be	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1615	10973	10980	treated	treat	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1616	10981	10985	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1617	10994	11002	platelet	platelet	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1618	11003	11015	glycoprotein	glycoprotein	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1619	11016	11019	IIb	iib	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1620	11019	11020	/	/	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1621	11020	11024	IIIa	iium	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1622	11025	11035	inhibitors	inhibitor	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1623	11035	11036	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1624	11037	11039	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1625	11040	11043	who	who	WP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1626	11044	11048	have	have	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1627	11057	11067	relatively	relatively	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1628	11068	11071	low	low	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1629	11072	11081	admission	admission	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1630	11082	11085	LDL	ldl	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1631	11086	11097	cholesterol	cholesterol	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1632	11098	11104	levels	level	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1633	11104	11105	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1634	11128	11132	Time	time	NNP	_	_	I-cesDoc	I-text	I-body	B-div	B-head	_	_
1635	11133	11135	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	I-head	_	_
1636	11136	11142	change	change	VB	_	_	I-cesDoc	I-text	I-body	I-div	I-head	_	_
1637	11143	11150	current	current	JJ	_	_	I-cesDoc	I-text	I-body	I-div	I-head	_	_
1638	11151	11159	practice	practice	NN	_	_	I-cesDoc	I-text	I-body	I-div	I-head	_	_
1639	11168	11176	Although	although	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
1640	11177	11183	MIRACL	miracl	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1641	11184	11187	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1642	11188	11191	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1643	11192	11195	two	two	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1644	11196	11210	aforementioned	aforemention	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1645	11211	11217	cohort	cohort	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1646	11226	11233	studies	study	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1647	11234	11241	suggest	suggest	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1648	11242	11246	that	that	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1649	11247	11261	lipid-lowering	lipid-lower	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1650	11262	11268	agents	agent	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1651	11269	11274	exert	exert	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1652	11275	11285	short-term	short-term	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1653	11294	11302	clinical	clinical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1654	11303	11311	benefits	benefit	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1655	11312	11316	when	when	WRB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1656	11317	11326	initiated	initiate	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1657	11327	11331	soon	soon	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1658	11332	11337	after	after	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1659	11338	11340	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1660	11341	11346	acute	acute	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1661	11355	11363	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1662	11364	11372	syndrome	syndrome	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1663	11372	11373	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1664	11374	11378	this	this	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1665	11379	11386	remains	remains	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1666	11387	11389	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1667	11390	11394	open	open	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1668	11395	11403	question	question	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1669	11403	11404	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1670	11405	11409	Even	even	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1671	11410	11412	if	if	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1672	11421	11426	these	these	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1673	11427	11435	findings	finding	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1674	11436	11439	are	be	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1675	11440	11443	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1676	11444	11453	confirmed	confirm	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1677	11454	11459	after	after	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1678	11460	11467	further	further	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1679	11468	11473	study	study	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1680	11473	11474	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1681	11475	11478	one	one	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1682	11487	11492	could	could	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1683	11493	11498	still	still	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1684	11499	11503	make	make	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1685	11504	11505	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1686	11506	11516	compelling	compell	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1687	11517	11525	argument	argument	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1688	11526	11530	that	that	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1689	11531	11545	lipid-lowering	lipid-lower	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1690	11554	11561	therapy	therapy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1691	11562	11563	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1692	11563	11570	barring	bar	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1693	11571	11588	contraindications	contraindication	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1694	11588	11589	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1695	11590	11596	should	should	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1696	11597	11599	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1697	11600	11609	initiated	initiate	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1698	11618	11623	early	early	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1699	11624	11627	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1700	11628	11639	universally	universally	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1701	11640	11642	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1702	11643	11651	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1703	11652	11655	who	who	WP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1704	11656	11663	present	present	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1705	11664	11668	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1706	11669	11671	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1707	11672	11677	acute	acute	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1708	11686	11694	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1709	11695	11703	syndrome	syndrome	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1710	11703	11704	:	:	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1711	11705	11710	First	first	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1712	11710	11711	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1713	11712	11715	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1714	11716	11725	long-term	long-term	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1715	11726	11732	safety	safety	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1716	11733	11736	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1717	11745	11758	effectiveness	effectiveness	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1718	11759	11761	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1719	11762	11769	statins	statin	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1720	11770	11773	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1721	11774	11777	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1722	11778	11787	secondary	secondary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1723	11788	11798	prevention	prevention	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1724	11799	11801	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1725	11811	11817	stable	stable	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	B-hi
1726	11818	11826	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1727	11827	11834	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1728	11835	11837	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1729	11846	11862	well-established	well-establish	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1730	11863	11864	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1731	11865	11866	1	1	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1732	11867	11868	2	2	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1733	11869	11870	3	3	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1734	11871	11872	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1735	11873	11874	;	;	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1736	11875	11881	Second	second	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1737	11881	11882	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1738	11883	11885	as	as	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1739	11886	11895	evidenced	evidence	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1740	11896	11898	by	by	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1741	11907	11913	MIRACL	miracl	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1742	11913	11914	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1743	11915	11920	these	these	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1744	11921	11927	agents	agent	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1745	11928	11931	are	be	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1746	11932	11936	safe	safe	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1747	11937	11941	when	when	WRB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1748	11942	11951	initiated	initiate	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1749	11952	11954	at	at	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1750	11955	11958	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1751	11959	11963	time	time	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1752	11964	11966	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1753	11975	11990	hospitalization	hospitalization	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1754	11991	11994	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1755	11995	11997	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1756	11998	12003	acute	acute	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1757	12004	12012	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1758	12013	12021	syndrome	syndrome	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1759	12021	12022	;	;	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1760	12023	12028	Third	third	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1761	12028	12029	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1762	12030	12033	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1763	12042	12053	in-hospital	in-hospital	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1764	12054	12064	initiation	initiation	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1765	12065	12067	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1766	12068	12082	lipid-lowering	lipid-lower	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1767	12083	12090	therapy	therapy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1768	12091	12098	appears	appear	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1769	12099	12101	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1770	12110	12117	promote	promote	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1771	12118	12125	greater	greater	JJR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1772	12126	12135	long-term	long-term	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1773	12136	12147	utilization	utilization	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1774	12148	12150	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1775	12151	12156	these	these	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1776	12157	12163	agents	agent	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1777	12164	12165	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1778	12166	12168	18	18	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1779	12177	12179	19	19	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1780	12180	12182	20	20	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1781	12183	12185	21	21	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1782	12186	12187	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1783	12188	12189	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1784	12190	12197	Finally	finally	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1785	12197	12198	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1786	12199	12207	although	although	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1787	12208	12213	lipid	lipid	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1788	12214	12220	levels	level	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1789	12221	12224	may	may	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1790	12225	12227	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1791	12236	12246	unreliable	unreliable	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1792	12247	12249	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1793	12250	12253	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1794	12254	12261	setting	set	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1795	12262	12264	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1796	12265	12267	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1797	12268	12273	acute	acute	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1798	12274	12282	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1799	12283	12291	syndrome	syndrome	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1800	12300	12301	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1801	12301	12310	excepting	except	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1802	12311	12316	total	total	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1803	12317	12318	:	:	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1804	12318	12321	HDL	hdl	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1805	12322	12325	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1806	12326	12329	LDL	ldl	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1807	12329	12330	:	:	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1808	12330	12333	HDL	hdl	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1809	12334	12345	cholesterol	cholesterol	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1810	12346	12352	ratios	ratio	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1811	12353	12354	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1812	12355	12357	22	22	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1813	12358	12359	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1814	12368	12369	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1815	12370	12373	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1816	12374	12386	overwhelming	overwhelm	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1817	12387	12395	majority	majority	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1818	12396	12398	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1819	12399	12407	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1820	12408	12412	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1821	12413	12421	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1822	12430	12437	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1823	12438	12442	will	will	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1824	12443	12453	ultimately	ultimately	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1825	12454	12461	require	require	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1826	12462	12466	both	both	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1827	12467	12480	pharmacologic	pharmacologic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1828	12481	12484	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1829	12493	12510	non-pharmacologic	non-pharmacologic	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1830	12511	12525	lipid-lowering	lipid-lower	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1831	12526	12539	interventions	intervention	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1832	12540	12542	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1833	12543	12549	attain	attain	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1834	12558	12569	recommended	recommend	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1835	12570	12581	cholesterol	cholesterol	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1836	12582	12589	targets	target	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1837	12590	12591	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1838	12592	12594	23	23	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1839	12595	12597	24	24	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1840	12598	12600	25	25	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1841	12601	12602	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1842	12603	12604	;	;	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1843	12605	12610	newer	newer	JJR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1844	12619	12629	guidelines	guideline	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1845	12630	12633	are	be	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1846	12634	12638	even	even	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1847	12639	12643	more	more	RBR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1848	12644	12653	stringent	stringent	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1849	12654	12655	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1850	12656	12658	26	26	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1851	12659	12660	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1852	12661	12662	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1853	12663	12674	Furthermore	furthermore	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1854	12674	12675	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1855	12684	12688	data	datum	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1856	12689	12693	from	from	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1857	12694	12697	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1858	12698	12706	recently	recently	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1859	12707	12716	presented	present	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1860	12717	12722	Heart	heart	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1861	12723	12733	Protection	protection	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1862	12734	12739	Study	study	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1863	12748	12755	suggest	suggest	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1864	12756	12760	that	that	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1865	12761	12769	clinical	clinical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1866	12770	12778	benefits	benefit	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1867	12779	12782	may	may	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1868	12783	12789	accrue	accrue	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1869	12790	12801	independent	independent	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1870	12802	12804	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1871	12813	12821	baseline	baseline	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1872	12822	12833	cholesterol	cholesterol	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1873	12834	12839	level	level	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1874	12840	12841	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1875	12842	12843	4	4	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1876	12844	12845	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1877	12846	12847	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1878	12848	12852	Thus	thus	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1879	12852	12853	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1880	12854	12856	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1881	12857	12865	withhold	withhold	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1882	12874	12888	lipid-lowering	lipid-lower	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1883	12889	12896	therapy	therapy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1884	12897	12901	from	from	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1885	12902	12910	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1886	12911	12914	who	who	WP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1887	12915	12922	present	present	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1888	12923	12927	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1889	12928	12930	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1890	12939	12944	acute	acute	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1891	12945	12953	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1892	12954	12962	syndrome	syndrome	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1893	12963	12968	would	would	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1894	12969	12971	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1895	12972	12974	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1896	12975	12981	accept	accept	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1897	12982	12985	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1898	12986	12992	status	status	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1899	12993	12996	quo	quo	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1900	12996	12997	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1901	13006	13009	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1902	13010	13012	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1903	13013	13017	date	date	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1904	13018	13021	our	our	PRP$	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1905	13022	13029	efforts	effort	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1906	13030	13032	at	at	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1907	13033	13044	cholesterol	cholesterol	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1908	13045	13053	lowering	lower	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1909	13054	13056	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1910	13057	13060	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1911	13069	13078	secondary	secondary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1912	13079	13089	prevention	prevention	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1913	13090	13097	setting	set	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1914	13098	13102	have	have	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1915	13103	13107	been	be	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1916	13108	13114	dismal	dismal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1917	13115	13116	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1918	13117	13119	27	27	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1919	13120	13122	28	28	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1920	13123	13124	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1921	13133	13134	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1922	13157	13161	More	more	JJR	_	_	I-cesDoc	I-text	I-body	B-div	B-head	_	_
1923	13162	13170	MIRACLes	miracle	NNP	_	_	I-cesDoc	I-text	I-body	I-div	I-head	_	_
1924	13171	13176	ahead	ahead	RB	_	_	I-cesDoc	I-text	I-body	I-div	I-head	_	_
1925	13176	13177	?	?	.	_	_	I-cesDoc	I-text	I-body	I-div	I-head	_	_
1926	13186	13189	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
1927	13190	13203	ascertainment	ascertainment	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1928	13204	13207	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1929	13208	13222	quantification	quantification	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1930	13223	13225	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1931	13226	13229	any	any	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1932	13230	13241	incremental	incremental	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1933	13250	13257	benefit	benefit	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1934	13258	13267	conferred	confer	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1935	13268	13270	by	by	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1936	13271	13277	statin	statin	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1937	13278	13285	therapy	therapy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1938	13286	13295	initiated	initiate	VBD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1939	13296	13301	early	early	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1940	13302	13307	after	after	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1941	13316	13318	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1942	13319	13324	acute	acute	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1943	13325	13333	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1944	13334	13342	syndrome	syndrome	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1945	13343	13347	will	will	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1946	13348	13355	require	require	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1947	13356	13368	confirmation	confirmation	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1948	13368	13369	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1949	13370	13375	There	there	EX	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1950	13384	13386	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1951	13387	13396	currently	currently	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1952	13397	13401	only	only	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1953	13402	13405	one	one	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1954	13406	13413	ongoing	ongo	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1955	13414	13424	randomized	randomize	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1956	13425	13443	placebo-controlled	placebo-controll	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1957	13452	13457	trial	trial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1958	13458	13460	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1959	13461	13466	early	early	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1960	13467	13473	versus	versus	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1961	13474	13481	delayed	delay	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1962	13482	13488	statin	statin	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1963	13489	13496	therapy	therapy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1964	13497	13499	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1965	13500	13504	this	this	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1966	13513	13520	setting	set	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1967	13520	13521	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1968	13522	13524	A-	a-	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1969	13524	13525	2	2	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1970	13525	13526	-	-	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1971	13526	13527	Z	z	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1972	13528	13529	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1973	13529	13538	Aggrastat	aggrastat	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1974	13539	13541	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1975	13542	13547	Zocor	zocor	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1976	13547	13548	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1977	13549	13554	Merck	merck	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1978	13554	13555	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1979	13556	13557	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1980	13558	13560	29	29	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1981	13561	13562	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1982	13563	13564	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1983	13565	13568	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1984	13577	13579	A-	a-	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1985	13579	13580	2	2	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1986	13580	13581	-	-	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1987	13581	13582	Z	z	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1988	13583	13588	study	study	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1989	13589	13591	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1990	13592	13602	evaluating	evaluate	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1991	13603	13606	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1992	13607	13615	efficacy	efficacy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1993	13616	13618	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1994	13619	13624	early	early	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1995	13625	13634	treatment	treatment	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1996	13643	13647	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1997	13648	13659	simvastatin	simvastatin	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1998	13660	13662	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
1999	13663	13668	4,500	4,500	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2000	13669	13677	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2001	13678	13687	following	follow	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2002	13688	13690	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2003	13691	13698	episode	episode	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2004	13699	13701	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2005	13710	13718	unstable	unstable	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2006	13719	13725	angina	angina	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2007	13726	13728	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2008	13729	13730	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2009	13731	13735	non-	non-	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2010	13735	13736	Q	q	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2011	13737	13741	wave	wave	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2012	13742	13752	myocardial	myocardial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2013	13753	13763	infarction	infarction	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2014	13763	13764	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2015	13765	13767	In	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2016	13776	13779	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2017	13780	13785	first	first	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2018	13786	13790	four	four	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2019	13791	13797	months	month	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2020	13797	13798	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2021	13799	13807	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2022	13808	13812	will	will	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2023	13813	13815	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2024	13816	13826	randomized	randomize	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2025	13827	13829	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2026	13838	13849	simvastatin	simvastatin	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2027	13850	13852	40	40	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2028	13853	13855	mg	mg	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2029	13856	13861	daily	daily	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2030	13862	13864	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2031	13865	13872	placebo	placebo	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2032	13872	13873	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2033	13874	13884	Thereafter	thereafter	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2034	13884	13885	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2035	13886	13891	those	those	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2036	13900	13908	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2037	13909	13916	treated	treat	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2038	13917	13921	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2039	13922	13933	simvastatin	simvastatin	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2040	13934	13936	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2041	13937	13940	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2042	13941	13946	first	first	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2043	13947	13952	phase	phase	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2044	13953	13957	will	will	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2045	13966	13973	receive	receive	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2046	13974	13976	80	80	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2047	13977	13979	mg	mg	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2048	13980	13982	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2049	13983	13994	simvastatin	simvastatin	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2050	13995	14000	daily	daily	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2051	14001	14004	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2052	14005	14010	those	those	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2053	14011	14018	treated	treat	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2054	14019	14023	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2055	14032	14039	placebo	placebo	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2056	14039	14040	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2057	14041	14043	40	40	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2058	14044	14046	mg	mg	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2059	14047	14049	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2060	14050	14061	simvastatin	simvastatin	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2061	14062	14067	daily	daily	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2062	14067	14068	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2063	14069	14072	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2064	14073	14080	primary	primary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2065	14081	14090	composite	composite	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2066	14099	14107	endpoint	endpoint	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2067	14108	14110	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2068	14111	14114	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2069	14115	14125	occurrence	occurrence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2070	14126	14128	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2071	14129	14143	cardiovascular	cardiovascular	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2072	14144	14149	death	death	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2073	14149	14150	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2074	14159	14168	non-fatal	non-fatal	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2075	14169	14179	myocardial	myocardial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2076	14180	14190	infarction	infarction	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2077	14190	14191	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2078	14192	14194	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2079	14195	14212	rehospitalization	rehospitalization	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2080	14213	14216	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2081	14225	14227	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2082	14228	14233	acute	acute	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2083	14234	14242	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2084	14243	14251	syndrome	syndrome	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2085	14252	14253	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2086	14253	14256	ACS	ac	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2087	14256	14257	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2088	14258	14260	at	at	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2089	14261	14264	one	one	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2090	14265	14269	year	year	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2091	14269	14270	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2092	14271	14273	If	if	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2093	14274	14276	A-	a-	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2094	14276	14277	2	2	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2095	14277	14278	-	-	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2096	14278	14279	Z	z	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2097	14288	14300	demonstrates	demonstrate	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2098	14301	14312	significant	significant	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2099	14313	14323	reductions	reduction	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2100	14324	14326	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2101	14327	14330	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2102	14331	14340	incidence	incidence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2103	14341	14343	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2104	14352	14359	adverse	adverse	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2105	14360	14366	events	event	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2106	14367	14373	during	during	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2107	14374	14377	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2108	14378	14383	first	first	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2109	14384	14388	four	four	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2110	14389	14395	months	month	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2111	14395	14396	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2112	14397	14399	it	it	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2113	14400	14405	would	would	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2114	14414	14421	suggest	suggest	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2115	14422	14424	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2116	14425	14436	incremental	incremental	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2117	14437	14445	clinical	clinical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2118	14446	14453	benefit	benefit	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2119	14454	14458	from	from	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2120	14459	14469	initiating	initiate	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2121	14478	14483	these	these	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2122	14484	14490	agents	agent	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2123	14491	14496	early	early	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2124	14497	14502	after	after	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2125	14503	14505	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2126	14506	14511	acute	acute	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2127	14512	14520	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2128	14521	14529	syndrome	syndrome	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2129	14529	14530	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2130	14531	14533	If	if	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2131	14542	14550	benefits	benefit	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2132	14551	14557	accrue	accrue	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2133	14557	14558	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2134	14559	14562	but	but	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2135	14563	14565	do	do	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2136	14566	14568	so	so	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2137	14569	14574	later	later	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2138	14575	14581	during	during	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2139	14582	14588	follow	follow	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2140	14589	14591	up	up	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2141	14591	14592	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2142	14593	14595	it	it	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2143	14596	14601	would	would	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2144	14610	14612	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2145	14613	14622	difficult	difficult	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2146	14623	14625	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2147	14626	14638	discriminate	discriminate	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2148	14639	14646	between	between	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2149	14647	14650	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2150	14651	14658	effects	effect	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2151	14659	14661	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2152	14662	14666	more	more	RBR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2153	14675	14685	aggressive	aggressive	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2154	14686	14689	vs.	vs.	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2155	14690	14697	earlier	earlier	JJR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2156	14698	14703	lipid	lipid	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2157	14704	14712	lowering	lower	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2158	14713	14720	therapy	therapy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2159	14720	14721	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2160	14730	14733	The	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
2161	14734	14745	Pravastatin	pravastatin	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2162	14746	14748	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2163	14749	14761	Atorvastatin	atorvastatin	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2164	14762	14772	Evaluation	evaluation	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2165	14773	14776	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2166	14777	14786	Infection	infection	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2167	14795	14802	Therapy	therapy	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2168	14803	14804	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2169	14804	14809	PROVE	prove	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2170	14810	14812	IT	it	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2171	14812	14813	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2172	14814	14819	trial	trial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2173	14820	14822	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2174	14823	14830	looking	look	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2175	14831	14833	at	at	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2176	14834	14839	4,000	4,000	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2177	14840	14848	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2178	14857	14863	within	within	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2179	14864	14866	10	10	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2180	14867	14871	days	day	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2181	14872	14874	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2182	14875	14877	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2183	14878	14883	acute	acute	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2184	14884	14892	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2185	14893	14901	syndrome	syndrome	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2186	14902	14905	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2187	14914	14925	randomizing	randomize	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2188	14926	14930	them	them	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2189	14931	14933	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2190	14934	14940	either	either	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2191	14941	14952	pravastatin	pravastatin	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2192	14953	14955	40	40	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2193	14956	14958	mg	mg	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2194	14959	14961	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2195	14970	14982	atorvastatin	atorvastatin	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2196	14983	14985	80	80	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2197	14986	14988	mg	mg	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2198	14989	14994	daily	daily	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2199	14995	14996	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2200	14997	14999	29	29	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2201	15000	15001	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2202	15002	15003	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2203	15004	15012	Patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2204	15013	15017	will	will	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2205	15018	15020	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2206	15021	15029	observed	observe	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2207	15038	15042	over	over	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2208	15043	15045	at	at	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2209	15046	15051	least	least	JJS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2210	15052	15055	1.5	1.5	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2211	15056	15061	years	year	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2212	15062	15065	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2213	15066	15069	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2214	15070	15080	occurrence	occurrence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2215	15081	15083	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2216	15084	15094	myocardial	myocardial	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2217	15103	15113	infarction	infarction	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2218	15114	15116	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2219	15117	15122	other	other	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2220	15123	15137	cardiovascular	cardiovascular	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2221	15138	15144	events	event	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2222	15144	15145	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2223	15146	15152	Unlike	unlike	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2224	15152	15153	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2225	15154	15160	MIRACL	miracl	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2226	15169	15172	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2227	15173	15176	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2228	15177	15179	A-	a-	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2229	15179	15180	2	2	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2230	15180	15181	-	-	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2231	15181	15182	Z	z	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2232	15183	15189	trials	trial	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2233	15189	15190	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2234	15191	15195	this	this	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2235	15196	15201	study	study	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2236	15202	15206	will	will	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2237	15207	15210	not	not	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2238	15211	15217	assess	assess	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2239	15218	15221	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2240	15230	15238	efficacy	efficacy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2241	15239	15241	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2242	15242	15247	early	early	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2243	15248	15254	statin	statin	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2244	15255	15262	therapy	therapy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2245	15263	15268	after	after	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2246	15269	15271	an	an	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2247	15272	15277	acute	acute	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2248	15278	15286	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2249	15295	15303	syndrome	syndrome	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2250	15303	15304	;	;	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2251	15305	15311	rather	rather	RB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2252	15311	15312	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2253	15313	15315	it	it	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2254	15316	15320	will	will	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2255	15321	15328	examine	examine	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2256	15329	15332	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2257	15333	15337	role	role	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2258	15338	15340	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2259	15350	15354	more	more	JJR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	B-hi
2260	15355	15358	vs.	vs.	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2261	15368	15372	less	less	RBR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	B-hi
2262	15373	15383	aggressive	aggressive	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2263	15384	15398	lipid-lowering	lipid-lower	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2264	15399	15401	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2265	15410	15414	this	this	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2266	15415	15422	setting	set	VBG	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2267	15422	15423	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2268	15432	15434	In	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
2269	15435	15439	2002	2002	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2270	15439	15440	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2271	15441	15445	many	many	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2272	15446	15451	would	would	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2273	15452	15460	consider	consider	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2274	15461	15463	it	it	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2275	15464	15473	unethical	unethical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2276	15474	15476	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2277	15477	15485	withhold	withhold	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2278	15494	15501	statins	statin	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2279	15502	15506	from	from	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2280	15507	15515	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2281	15516	15520	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2282	15521	15532	established	establish	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2283	15533	15541	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2284	15542	15549	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2285	15549	15550	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2286	15559	15563	This	this	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2287	15564	15569	makes	make	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2288	15570	15572	it	it	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2289	15573	15581	unlikely	unlikely	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2290	15582	15586	that	that	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2291	15587	15597	additional	additional	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2292	15598	15616	placebo-controlled	placebo-controll	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2293	15625	15631	trials	trial	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2294	15632	15636	will	will	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2295	15637	15639	be	be	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2296	15640	15647	carried	carry	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2297	15648	15651	out	out	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2298	15652	15654	in	in	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2299	15655	15659	this	this	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2300	15660	15664	area	area	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2301	15664	15665	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2302	15666	15672	Future	future	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2303	15673	15682	secondary	secondary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2304	15691	15701	prevention	prevention	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2305	15702	15709	studies	study	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2306	15710	15716	should	should	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2307	15717	15721	look	look	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2308	15722	15724	at	at	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2309	15725	15733	patients	patient	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2310	15734	15738	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2311	15739	15745	stable	stable	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2312	15755	15757	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	B-hi
2313	15758	15766	unstable	unstable	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2314	15767	15774	disease	disease	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2315	15775	15778	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2316	15779	15783	will	will	MD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2317	15784	15788	need	need	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2318	15789	15791	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2319	15800	15807	address	address	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2320	15808	15811	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2321	15812	15823	comparative	comparative	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2322	15824	15832	efficacy	efficacy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2323	15833	15835	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2324	15836	15845	different	different	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2325	15846	15853	statins	statin	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2326	15854	15855	(	(	(	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2327	15855	15857	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2328	15866	15871	newer	newer	JJR	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2329	15872	15878	agents	agent	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2330	15878	15879	)	)	)	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2331	15879	15880	,	,	,	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2332	15881	15887	assess	assess	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2333	15888	15891	the	the	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2334	15892	15903	incremental	incremental	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2335	15904	15911	benefit	benefit	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2336	15912	15914	of	of	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2337	15923	15934	combination	combination	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2338	15935	15942	therapy	therapy	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2339	15943	15944	[	[	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2340	15945	15947	30	30	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2341	15948	15949	]	]	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2342	15950	15953	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2343	15954	15963	determine	determine	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2344	15964	15971	whether	whether	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2345	15972	15977	there	there	EX	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2346	15978	15980	is	be	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2347	15981	15982	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2348	15991	15996	serum	serum	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2349	15997	16008	cholesterol	cholesterol	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2350	16009	16010	'	'	''	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2351	16010	16015	floor	floor	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2352	16015	16016	'	'	''	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2353	16017	16022	below	below	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2354	16023	16028	which	which	WDT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2355	16029	16039	reductions	reduction	NNS	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2356	16040	16043	are	be	VBP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2357	16052	16060	unlikely	unlikely	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2358	16061	16063	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2359	16064	16071	provide	provide	VB	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2360	16072	16079	further	further	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2361	16080	16088	clinical	clinical	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2362	16089	16096	benefit	benefit	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2363	16096	16097	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2364	16120	16129	Competing	compete	VBG	_	_	I-cesDoc	I-text	I-body	B-div	B-head	_	_
2365	16130	16139	interests	interest	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	I-head	_	_
2366	16148	16150	Dr	dr	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
2367	16151	16157	Aronow	aronow	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2368	16158	16161	has	have	VBZ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2369	16162	16170	received	receive	VBN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2370	16171	16180	honoraria	honorarium	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2371	16181	16183	as	as	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2372	16184	16185	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2373	16186	16193	speaker	speaker	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2374	16194	16197	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2375	16206	16214	advisory	advisory	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2376	16215	16220	board	board	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2377	16221	16227	member	member	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2378	16228	16231	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2379	16232	16238	Pfizer	pfizer	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2380	16239	16242	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2381	16243	16245	as	as	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2382	16246	16247	a	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2383	16248	16255	speaker	speaker	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2384	16256	16259	for	for	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2385	16268	16273	Merck	merck	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2386	16273	16274	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2387	16297	16310	Abbreviations	abbreviation	NNP	_	_	I-cesDoc	I-text	I-body	B-div	B-head	_	_
2388	16319	16322	HMG	hmg	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	B-p	_
2389	16323	16326	CoA	coa	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2390	16327	16328	=	=	SYM	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2391	16329	16355	3-Hydroxy-3-methylgluatryl	3-hydroxy-3-methylgluatryl	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2392	16356	16364	coenzyme	coenzyme	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2393	16365	16366	A	a	DT	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2394	16366	16367	;	;	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2395	16368	16374	MIRACL	miracl	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2396	16383	16384	=	=	SYM	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2397	16385	16395	Myocardial	myocardial	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2398	16396	16404	Ischemia	ischemium	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2399	16405	16414	Reduction	reduction	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2400	16415	16419	with	with	IN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2401	16420	16430	Aggressive	aggressive	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2402	16431	16442	Cholesterol	cholesterol	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2403	16451	16459	Lowering	lower	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2404	16459	16460	;	;	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2405	16461	16464	LDL	ldl	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2406	16465	16466	=	=	SYM	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2407	16467	16470	low	low	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2408	16471	16478	density	density	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2409	16479	16490	lipoprotein	lipoprotein	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2410	16490	16491	;	;	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2411	16492	16494	RR	rr	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2412	16495	16496	=	=	SYM	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2413	16497	16505	relative	relative	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2414	16514	16518	risk	risk	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2415	16518	16519	;	;	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2416	16520	16522	CI	cus	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2417	16523	16524	=	=	SYM	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2418	16525	16535	confidence	confidence	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2419	16536	16544	interval	interval	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2420	16544	16545	;	;	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2421	16546	16549	HDL	hdl	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2422	16550	16551	=	=	SYM	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2423	16552	16556	high	high	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2424	16557	16564	density	density	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2425	16573	16584	lipoprotein	lipoprotein	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2426	16584	16585	;	;	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2427	16586	16590	PTCA	ptca	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2428	16591	16592	=	=	SYM	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2429	16593	16605	percutaneous	percutaneous	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2430	16606	16618	transluminal	transluminal	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2431	16619	16627	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2432	16636	16647	angioplasty	angioplasty	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2433	16647	16648	;	;	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2434	16649	16653	CABG	cabg	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2435	16654	16655	=	=	SYM	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2436	16656	16664	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2437	16665	16671	artery	artery	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2438	16672	16678	bypass	bypass	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2439	16679	16684	graft	graft	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2440	16684	16685	;	;	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2441	16686	16689	ECG	ecg	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2442	16690	16691	=	=	SYM	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2443	16700	16717	electrocardiogram	electrocardiogram	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2444	16717	16718	;	;	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2445	16719	16721	A-	a-	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2446	16721	16722	2	2	CD	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2447	16722	16723	-	-	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2448	16723	16724	Z	z	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2449	16725	16726	=	=	SYM	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2450	16727	16736	Aggrastat	aggrastat	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2451	16737	16739	to	to	TO	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2452	16740	16745	Zocor	zocor	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2453	16745	16746	;	;	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2454	16747	16750	ACS	ac	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2455	16751	16752	=	=	SYM	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2456	16753	16758	acute	acute	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2457	16767	16775	coronary	coronary	JJ	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2458	16776	16784	syndrome	syndrome	NN	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2459	16784	16785	;	;	:	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2460	16786	16791	PROVE	prove	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2461	16792	16794	IT	it	PRP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2462	16795	16796	=	=	SYM	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2463	16797	16808	Pravastatin	pravastatin	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2464	16809	16811	or	or	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2465	16812	16824	Atorvastatin	atorvastatin	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2466	16833	16843	Evaluation	evaluation	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2467	16844	16847	and	and	CC	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2468	16848	16857	Infection	infection	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2469	16858	16865	Therapy	therapy	NNP	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_
2470	16865	16866	.	.	.	_	_	I-cesDoc	I-text	I-body	I-div	_	I-p	_

